Artiva Biotherapeutics, Inc. (ARTV) is a NASDAQ-listed, clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies for autoimmune diseases and blood cancers, led by its AlloNK candidate in lupus (systemic lupus erythematosus). As a pre-revenue biotech, its analyst price targets hinge almost entirely on clinical-trial probability, which explains the extraordinarily wide range.
A review of the attributed targets found a low of $4 and a high of $41, with the calculated mean near $22. The dispersion is stark. In late October 2026, Jefferies cut its rating to Hold from Buy and lowered its target to $4 from $23, while TD Cowen analyst Gil Blum also moved to a $4 target. In contrast, Cantor Fitzgerald reiterated an Overweight rating with a $40 target in early October, and Needham held a Buy with a $41 target. Independent aggregators report a comparable average in the low-to-mid $20s, though the mix of one sell, several hold, and a couple of buy ratings means there is no genuine consensus — only a wide spread of conviction about whether AlloNK can succeed.
ARTV traded around $4.22 in early November 2026, well below its 52-week high of $14.53 and nearer its 52-week low of $2.96. Its market capitalization is roughly $200 million, and trailing EPS (earnings per share) is about negative $3.23, reflecting deep operating losses as it funds clinical development.
To reach $22, the stock would need to gain roughly 421%, a very large move that would require it not merely to recover its prior 52-week high but to break decisively above it. That kind of rerating in a clinical-stage biotech typically follows a positive, statistically meaningful data readout that materially de-risks a lead program. In the absence of such a catalyst, the path is far less defined, and the shares could remain anchored near the low end of the analyst range.
The bull case rests on the autoimmune opportunity for AlloNK and the broader NK-cell platform. Allogeneic, "off-the-shelf" cell therapies could, if validated, offer advantages over personalized treatments in cost, logistics, and accessibility. The company also carries a substantial cash position of roughly $349 million, which funds a multi-year runway and reduces near-term dilution risk. Long-standing holders such as RA Capital Management and Viking Global Investors underscore institutional backing. Finally, the retention of two bullish targets near $40 signals that some analysts still assign meaningful probability to clinical success, and any positive lupus data or favorable regulatory feedback could re-rate the shares sharply.
The principal obstacle is binary clinical risk: if AlloNK's trials fail to show safety or efficacy, the bull thesis collapses and the stock could retest or break its 52-week low. The October 2026 downgrades to $4 indicate that several analysts already see limited near-term upside and elevated downside. As a pre-revenue company, ARTV generates no sales to cushion setbacks, and continued losses will consume cash over time. Valuation offers no floor tied to earnings, so the shares are driven by sentiment, trial milestones, and financing decisions rather than fundamentals. A failed trial, a delay, or a dilutive capital raise could each push the price lower and keep $22 out of reach.
The chart tells a story of sustained decline: after trading as high as $14.53, ARTV has fallen into the low single digits. The 52-week low near $2.96 represents the most important downside support, while the $4 level — where several analyst targets now cluster — functions as a psychological and consensus-anchored zone. On the upside, the prior high of $14.53 is the first major landmark a recovery would need to reclaim, and the $22 target sits far above it. The share count recently increased substantially, which dilutes existing holders and adds supply overhang that can weigh on any rally.
Analyst price targets for equities generally reflect a research horizon of roughly 12 months, though for a clinical-stage biotech the effective catalyst calendar matters more than the calendar. The next earnings report, expected around November 12, 2026, is a near-term checkpoint for cash burn and any pipeline commentary. Beyond that, investors should watch for AlloNK lupus data readouts, trial enrollment updates, regulatory interactions, additional analyst rating changes, and any financing activity. Because the rating distribution is so divided, new data that shifts probability will likely trigger immediate target revisions in one direction or the other.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like ARTV, where sentiment and technicals can shift rapidly between clinical catalysts, automated scanning can help traders discover opportunities, monitor positions, and spot changing trends more efficiently than manual chart review. Traders looking to complement fundamental research with systematic, data-driven signals can explore these AI tools to stay ahead of fast-moving price action.
Can ARTV reach $22? The central target is the arithmetic mean of a strikingly divergent set of analyst forecasts ranging from $4 to $41. From a price near $4.22, that represents a very large required advance of roughly 421%, a move that would demand a meaningful clinical or strategic catalyst rather than incremental progress. The strongest supports are the cash runway and the autoimmune NK-cell opportunity; the principal obstacles are binary trial risk, a pre-revenue profile, and the recent downgrades that have anchored near-term expectations at $4. The split between $4 and $41 targets is itself the story: this is a company whose value rests on outcomes that have not yet been determined. Investors should monitor trial data, guidance, and analyst revisions closely, without treating the mean target as either a guarantee or a precise forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ARTV has been loosely correlated with RADX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ARTV jumps, then RADX could also see price increases.
| Ticker / NAME | Correlation To ARTV | 1D Price Change % | ||
|---|---|---|---|---|
| ARTV | 100% | -3.79% | ||
| RADX - ARTV | 44% Loosely correlated | -3.95% | ||
| KYTX - ARTV | 37% Loosely correlated | -1.74% | ||
| CELC - ARTV | 34% Loosely correlated | -4.72% | ||
| AURA - ARTV | 32% Poorly correlated | -0.13% | ||
| IRON - ARTV | 32% Poorly correlated | +4.16% | ||
More | ||||